Cerity Partners LLC Purchases 2,454 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Cerity Partners LLC raised its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 33.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,846 shares of the medical instruments supplier’s stock after acquiring an additional 2,454 shares during the period. Cerity Partners LLC’s holdings in ICU Medical were worth $1,794,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ICUI. Innealta Capital LLC purchased a new position in ICU Medical during the second quarter worth $32,000. Hexagon Capital Partners LLC raised its holdings in shares of ICU Medical by 162.7% in the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares in the last quarter. Allworth Financial LP lifted its holdings in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the period. Venturi Wealth Management LLC lifted its stake in shares of ICU Medical by 1,510.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 302 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of ICU Medical in the 2nd quarter worth approximately $70,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at ICU Medical

In other news, Director David C. Greenberg sold 972 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the transaction, the director now owns 5,037 shares in the company, valued at $796,400.07. This trade represents a 16.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $178.46, for a total value of $2,141,520.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,364 shares of company stock worth $6,869,878 over the last 90 days. Corporate insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Raymond James upped their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. KeyCorp lifted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Finally, Jefferies Financial Group initiated coverage on ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, ICU Medical presently has an average rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Trading Down 1.8 %

NASDAQ ICUI opened at $160.96 on Tuesday. ICU Medical, Inc. has a 52 week low of $83.26 and a 52 week high of $196.26. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $3.94 billion, a PE ratio of -35.22 and a beta of 0.66. The firm has a 50 day moving average of $174.60 and a two-hundred day moving average of $147.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.